Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice

Yi Liu; Li Zhu; Zuopo Lv; Liping Mao; Chao Hu; Jinghan Wang; Yile Zhou; Jie Jin; Haitao Meng; Liangshun You

doi:10.1111/bjh.18788

Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice

Br J Haematol. 2023 Jun;201(5):995-999. doi: 10.1111/bjh.18788. Epub 2023 Mar 31.

Authors

Yi Liu^{1

2}, Li Zhu^{1

2}, Zuopo Lv^{1

2}, Liping Mao^{1

2}, Chao Hu^{1

2

3}, Jinghan Wang^{1

2

3}, Yile Zhou^{1

2

3}, Jie Jin^{1

2

3}, Haitao Meng^{1

2

3}, Liangshun You^{1

2

3}

Affiliations

¹ Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, People's Republic of China.
² Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, 310003, Zhejiang, People's Republic of China.
³ Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, 310003, Zhejiang, People's Republic of China.

PMID: 36999439
DOI: 10.1111/bjh.18788

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Azacitidine / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
Humans
Leukemia, Myeloid, Acute* / drug therapy
Sulfonamides / therapeutic use

Substances

venetoclax
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
Azacitidine